REGN 240913 1190.00C (REGN240913C1190000) Stock Options, News & Quotes

0.99
0.000.00%

15min DelayTrading Sep 12 15:37 ET

0.00High0.00Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Meltyy

Sep 10 04:37

📅 FDA PDUFA & AdCom Update…

📣 ITRM AdCom 9/9 meeting ongoing 🚗
👀 stay tuned for updates on meeting outcomes
See 👇 for further info.
🚨 This Week’s AdCom:
$Iterum Therapeutics (ITRM.US)$ : Meeting ongoing 🤔
⇨ Sulopenem
‣ uUTI (Uncomplicated Urinary Tract Infection)
‣ AdCom: 9/9/24
🚨 Last Week’s PDUFAs:
$Travere Therapeutic (TVTX.US)$ : Approved 9/5 🎉
⇨ FILSPARI (Sparsentan)
‣ IgA nephropathy (IgAN)
‣ PDUFA: 9/5/24
$Avadel Pharmaceuticals (AVDL.US)$ : Awaiting decision 🤔
⇨ LUMRYZ (sodium oxybate)
‣...

Analysts Notebook

Aug 27 06:33

Columns Ready for Fed Rate Cuts? Biotech's Potential to Watch

The Federal Reserve appears poised to cut interest rates later this year. While the broader stock market might breathe a sigh of relief, certain sectors could be more significantly impacted than others. Biotechnology could be one of those sectors - at least, that's what Morgan Stanley believes.
In 2024, biotech stocks had a slow start, with the S&P Biotechnology Select Industry Index returning just under 4% in the first six months, compared to...

FOMC preview: How might a potential rate cut reshape investment landscape?

Meltyy

Aug 27 01:16

FDA PDUFA Update:

🚀 Buckle up for upcoming PDUFAs in September! 👇
$Travere Therapeutic (TVTX.US)$ : FILSPARI (Sparsentan)
$Avadel Pharmaceuticals (AVDL.US)$ : LUMRYZ (FT218)
$Iterum Therapeutics (ITRM.US)$ : Sulopenem - AdCom 🗓️
$Sanofi (SNY.US)$ & $Regeneron Pharmaceuticals (REGN.US)$ : Dupixent
$Vanda Pharmaceuticals (VNDA.US)$ : Tradipitant
$Zevra Therapeutics (ZVRA.US)$ : Arimoclomol
$Heron Therapeutics (HRTX.US)$ : ZYNRELEF® Vial Access Needle
$Merck & Co (MRK.US)$ : KEYTRUDA+ chemotherapy
$Bristol-Myers Squibb (BMY.US)$ : KarXT (...

frankinglily

Aug 25 22:03

Argument:
The upcoming interest rate cuts are poised to benefit the biotech stock industry, setting the stage for strong performance in the coming quarters.
Reasons:
Cheaper Funding: Lower interest rates make it easier for biotech companies to access capital for research and development, accelerating their progress and growth potential.
Attractive Valuations: Biotech stocks are currently trading at attractive levels, offering investors an opportunity to capitalize on the sector's long-term pot...

Powell said it's time to cut: Will the market go wild?

In One Chart

Aug 22 07:58

Columns In One Chart | Wall Street Eyes New Sectors for the Next Stock Market Surge

Recent data shows that defensive sectors like utilities, consumer defensive, and healthcare have outperformed the information technology sector over the past month, reaching 52-week highs.
Notably, several stocks within these sectors have shown exceptional performance. Pharmaceutical giants with market values in the hundreds of billions, such as $Eli Lilly and Co (LLY.US)$, $Thermo Fisher Scientific (TMO.US)$, $AbbVie (ABBV.US)$, and ...

Payrolls revised downward: Where are U.S. stocks headed?

273

111